- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00452387
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to test the hypothesis that the combination of Mitoxantrone, Prednisone and Sorafenib in taxane-refractory patients with metastatic hormone refractory prostate cancer (mHRPC) will result in an improvement of the median time to progression (TTP). Since the median (i.e 50% of patients) TTP for Mitoxantrone/Prednisone is 3 months, our hypothesis is that 70% will have not progressed at 3 months with this investigational combination. Progression will be assessed by radiologic imaging criteria.
The early stopping point is 21 subjects. If 10 or fewer subjects with tumor favorable response are observed when 21 subjects are accrued then the null hypothesis is accepted and the trial is terminated. If 16 or more subjects with tumor favorable response are observed when 21 subjects are accrued then the alternative hypothesis is accepted and the trial is terminated. The probability of early stopping under the null is 0.51, and under the alternative is 0.39. If the trial progresses until 42 subjects are evaluated and 24 or more subjects with favorable response are observed then the null hypothesis is rejected. This design minimizes the average sample number under the null, which is 31.2.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
La Verne, California, United States, 91750
- Wilshire Oncology Medical Group, Inc.
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Peachtree Hematology Oncology Consultants
-
Macon, Georgia, United States, 31201
- Central Georgia Cancer Care
-
Marietta, Georgia, United States, 30060
- Northwest Georgia Oncology Centers
-
-
Montana
-
Billings, Montana, United States, 59101
- Hematology Oncology Centers of the Northern Rockies, PC
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Mid-Ohio Oncology/Hematology, Inc.
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17605
- Lancaster Cancer Center
-
Philadelphia, Pennsylvania, United States, 19106
- Pennsylvania Oncology Hematmology Associates
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
-
Virginia
-
Chesapeake, Virginia, United States, 23320
- Cancer Specialists of Tidewater
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary written informed consent
- Histopathologic diagnosis of prostatic adenocarcinoma with evidence of progression despite adequate castration (testosterone < 50 ng/dL)
- Progressive disease after taxane-based chemotherapy (docetaxel or paclitaxel, single agent or combination regimens, weekly or every 21 day schedules)
- Patients who discontinued taxane- based chemotherapy because of toxicity will be eligible as long as there is evidence of progressive disease
- Minimum of 4 weeks period from last chemotherapy infusion to registration (this does not apply to steroid use which is permitted). Estramustine needs to be discontinued at least 6 weeks prior to first day of treatment on protocol
- A minimum of 4 weeks off bicalutamide, nilutamide, megestrol acetate ketoconazole, diethylstilbestrol (DES). Minimum of 2 weeks off flutamide
- Reductase inhibitors will be allowed if initiated at least 2 months prior to registration
- No concurrent investigational therapy
- Complementary and Alternative Medicine (CAM) products will be permitted as long as patients have been receiving them for at least 2 months. Initiation of new CAM products while on protocol will be discouraged.
- Ongoing androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone (GnRH) agonist or antagonist)
Adequate bone marrow, liver and renal function as assessed by the following:
- Hemoglobin ≥ 9.0 g/dl
- Absolute neutrophil count (ANC) ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times the ULN ( ≤ 5 x ULN for patients with liver involvement)
- Creatinine ≤ 1.5 times the ULN
- International normalized ratio (INR) < 1.5 or a Prothrombin (PT)/Partial thromboplastin time (PTT) within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
- ECOG performance status ≤ 2
- Baseline left ventricular ejection fraction (LVEF) ≥ 50%
- Life expectancy ≥ 3 months
- Patients must agree to use adequate contraception prior to study entry, during the study and for at least three months after the last administration of sorafenib
Exclusion Criteria:
- More than one line of prior cytotoxic chemotherapy in the metastatic setting, previous adjuvant chemotherapy will be allowed
- No active malignancy other than prostate cancer (except non-melanoma skin cancer) within 5 years of enrollment
- Known brain metastases
- Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Uncontrolled hypertension
- Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
- Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of study drug
- Poorly controlled hyperglycemia
- Treatment with radiotherapy within 4 weeks or treatment with radiopharmaceuticals within past 8 weeks
- Patient has received other investigational drugs within 14 days before enrollment
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Serious non-healing wound or ulcer
- Evidence or history of bleeding diathesis or coagulopathy
- Use of St. John's Wort or rifampin
- Known or suspected allergy to sorafenib or any agent given in the course of this trial
- Any condition that impairs patient's ability to swallow whole pills
- Any malabsorption problem
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Time to Progression (TTP) by Imaging
Time Frame: Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Time to progression is defined as the time from treatment start until objective tumor progression.
The median time to progression is the parameter used to describe TTP.
|
Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of Biochemical Criteria (PSA, Prostate-specific Antigen) With Objective Imaging
Time Frame: PSA was evaluated on day 1 of every cycle (approximately every 3 weeks) during study treatment. Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
The test of association assesses the null hypothesis that the frequency of PSA response is the same for patients with and without a favorable imaging response.
PSA response required a 50% reduction of the baseline PSA result that was confirmed three weeks later.
Favorable imaging response is defined as stable disease, partial response, or complete response per RECIST guidelines.
The Fisher's exact test was used to test this hypothesis.
|
PSA was evaluated on day 1 of every cycle (approximately every 3 weeks) during study treatment. Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.
|
Quality of Life (QoL)
Time Frame: The Patient Care Monitor questionnaire was administered on day 1 of every cycle (approximately every 3 weeks) during study treatment.
|
The subject answers questions from the following 6 categories: general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation.
Each question has a scale from 0 through 10, where 0 is not a problem and 10 is as bad as possible.
The scores for the 6 categories are combined and normalized, and used to describe overall quality of life.
Because normalized scores are created using a look-up index, there is no clearly defined maximum value.
In practice, the maximum value for the combined scale is 73.5.
|
The Patient Care Monitor questionnaire was administered on day 1 of every cycle (approximately every 3 weeks) during study treatment.
|
Median Overall Survival (OS)
Time Frame: Overall survival was measured from day 1 of treatment until the end of treatment and then every 3 months thereafter until death.
|
Overall survival is defined as the time from treatment start until death from any cause.
The median overall survival time is used to measure OS.
|
Overall survival was measured from day 1 of treatment until the end of treatment and then every 3 months thereafter until death.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Vasily Assikis, MD, Peachtree Hematology Oncology Consultants
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Sorafenib
- Prednisone
- Mitoxantrone
Other Study ID Numbers
- ACORN AVAHRPC0607
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Prostate Cancer
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstituteEpizyme, Inc.; PfizerRecruitingMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on Mitoxantrone
-
PD Dr. Andrew ChanUnknown
-
Institute of Hematology & Blood Diseases Hospital...CSPC Ouyi Pharmaceutical Co., Ltd.Active, not recruiting
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical GroupRecruitingAngioimmunoblastic T-cell LymphomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Withdrawn
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Hope Cancer Institute, Inc.UnknownProstate CancerUnited States
-
Lederle LaboratoriesCompletedHIV Infections | Sarcoma, KaposiUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedAdvanced Gastric CarcinomaChina